Angiogenesis in hematologic malignancies

被引:56
作者
Moehler, TM [1 ]
Neben, K [1 ]
Ho, AD [1 ]
Goldschmidt, H [1 ]
机构
[1] Heidelberg Univ, Dept Internal Med 5, D-69115 Heidelberg, Germany
关键词
angiogenesis; vasculogenesis; leukemia; lymphoma; multiple myeloma;
D O I
10.1007/s00277-001-0398-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiogenesis defined as the blood vessel generation from preexisting blood vessels was found to play an important role in the progression of solid tumors. In addition, bone marrow-derived endothelial precursor cells may contribute to tumor angiogenesis. Recently angiogenesis induction was described in several hematologic neoplasms as leukemia, lymphoma, myelodysplastic syndrome and multiple myeloma (MM). Clinical angiogenesis research also termed as angiodiagnosis has established the prognostic relevance of markers of angiogenesis e.g., microvessel density and circulating levels of angiogenic peptides. Development of antiangiogenic treatment for hematologic neoplasms has recently been sparked by the success of Thalidomide (Thal) which has antiangiogenic properties in MM. Antiangiogenic treatment strategies are now being tested in clinical trials on several types of hematologic neoplasms.
引用
收藏
页码:695 / 705
页数:11
相关论文
共 129 条
[71]   Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia [J].
Kini, AR ;
Kay, NE ;
Peterson, LC .
LEUKEMIA, 2000, 14 (08) :1414-1418
[72]   Angiogenesis in acute promyelocytic leukemia:: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid [J].
Kini, AR ;
Peterson, LC ;
Tallman, MS ;
Lingen, MW .
BLOOD, 2001, 97 (12) :3919-3924
[73]   Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity [J].
Klement, G ;
Baruchel, S ;
Rak, J ;
Man, S ;
Clark, K ;
Hicklin, DJ ;
Bohlen, P ;
Kerbel, RS .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (08) :R15-R24
[74]   Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas [J].
Kossakowska, AE ;
Edwards, DR ;
Prusinkiewicz, C ;
Zhang, MC ;
Guo, DL ;
Urbanski, SJ ;
Grogan, T ;
Marquez, LA ;
Janowska-Wieczorek, A .
BLOOD, 1999, 94 (06) :2080-2089
[75]   MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL) [J].
Kuittinen, O ;
Savolainen, ER ;
Koistinen, P ;
Möttönen, M ;
Turpeenniemi-Hujanen, T .
LEUKEMIA RESEARCH, 2001, 25 (02) :125-131
[76]   Synergy between an antiangiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases [J].
Lode, HN ;
Moehler, T ;
Xiang, R ;
Jonczyk, A ;
Gillies, SD ;
Cheresh, DA ;
Reisfeld, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (04) :1591-1596
[77]   Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [J].
Maisonpierre, PC ;
Suri, C ;
Jones, PF ;
Bartunkova, S ;
Wiegand, S ;
Radziejewski, C ;
Compton, D ;
McClain, J ;
Aldrich, TH ;
Papadopoulos, N ;
Daly, TJ ;
Davis, S ;
Sato, TN ;
Yancopoulos, GD .
SCIENCE, 1997, 277 (5322) :55-60
[78]   Angiogenesis and angiogenic mediators in haematological malignancies [J].
Mangi, MH ;
Newland, AC .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) :43-51
[79]   Vascular channel formation by human melanoma cells in vivo and in vitro:: Vasculogenic mimicry [J].
Maniotis, AJ ;
Folberg, R ;
Hess, A ;
Seftor, EA ;
Gardner, LMG ;
Pe'er, J ;
Trent, JM ;
Meltzer, PS ;
Hendrix, MJC .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (03) :739-752
[80]   Combined effects of angiostatin and ionizing radiation in antitumour therapy [J].
Mauceri, HJ ;
Hanna, NN ;
Beckett, MA ;
Gorski, DH ;
Staba, MJ ;
Stellato, KA ;
Bigelow, K ;
Heimann, R ;
Gately, S ;
Dhanabal, M ;
Soff, GA ;
Sukhatme, VP ;
Kufe, DW ;
Weichselbaum, RR .
NATURE, 1998, 394 (6690) :287-291